YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Antiplatelet Activity of 2-(4-Cyanophenyl) amino-1,4-naphthalenedione-3-pyridinium perchlorate (PQ5)

2-(4-시아노페닐) 아미노 -1,4-나프탈렌디온-3-피리디니움 퍼클로레이트 (PQ5)의 항혈소판작용

  • Published : 1999.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

The effect of 2-(4-cyanophenyl)amino-1,4-naphthalenedione-3-pyridinium perchlorate (PQ5) on pla-telet aggregation and its action mechanisms were investigated with rat platelet. PQ5 inhibited the platelet aggregation induced by collagen ($6{\;}{\mu\textrm{g}}/ml$), thrombin (0.4 U/ml) and A23187 ($3{\mu}M$) in concentration-dependent manner with $IC_{50}$ values of 5.50, 25.89 and $37.12{\;}{\mu}M$, respectively. PQ5 also significantly reduced the thromboxane $A_2$ (TXA2) formation in a concentration dependent manner. The collagen-induced arachidonic acid (AA) release in [-3H]-AA incorporated platelet, an indication of the phospholipase $A_2$ activity, was decreased by PQ5 pretreatment PQ5 significantly inhibited the activity of thormboxane synthase only at high concentration ($100{\mu}M$), but did not affect the cyclooxygenase activity at all. Collagen-induced ATP release was significantly reduced by PQ5. Calcium-induced platelet aggregation experiment suggests that the elevation of intracellular free $Ca^{2+}$ concentration ($[Ca^{2+}]_i$) by collagen stimulation is decreased by the pretreatment of PQ5, which is due to the inhibition of calcium release from intracellular store and influx from outside of the cell. PQ5 did not showed the effect of anticoagulation as prothrombin time (PT) or activated partial thromboplastin time (APTT). Form these results, it is suggested that PQ5 exerts its antiplatelet activity through the inhibition of the intracellular $Ca^{2+}$ mobilization and the decrease of the $TXA_2$ synthesis.

Keywords

References

  1. Can. J. Physiol. Pharmacol. v.72 The role of platelets in thrombosis and hemostasis Packham, M. A.
  2. Can. J. Physiol. Pharmacol. v.72 Platelets, vascular disease and diabetes mellitus Winocour, P. D.
  3. Blood Rev. v.9 Platelet activation Blockmans, D.;Deckmyn, H.;Vermylen, J.
  4. Biochim. Biophys. Acta v.1175 Intracellular calcium mobilization in rat platelets is adversely affected byt copper deficiency Johnson, W. T.;Dufault, S. N.
  5. Drugs and the delivery of oxygen to tissue Platelet activation and drugs that modify platelet function Meanwell, N. A.;Seiler, S. M.;Fleming, J.S.(Ed.)
  6. Pharmacol Rev. v.43 no.3 Pharmacological receptors on blood platelets Hourani, S. M. O.;Cusack, N. J.
  7. Am. J. Cardiol. Mechanism of platelet activation: thromboxane A₂as an amplifying signal for other agonists FitzGerald, G. A.
  8. Thromb. Res. v.37 Inhibition of human platelet aggregation by vitamin K Blackwell, G. J.;Radomski, M.;Moncada, S.
  9. Thromb. Res. v.57 Inhibition of rabbit platelet aggregation by 1,4-naphthoquinones Ko, F. N.Sheu, S. J.;Lin, Y. M.;Huang, T. F.;Teng, C. M.
  10. Bioorg. Med. Chem. v.6 no.12 Synthesis and antiplatelet, antiinflammatory, and antiallergic activities of substituted-chloro-5,8-dimethoxy-1,4-naphthoquinone and related compounds Huang, L. J.;Chang, F. C.;Lee, K. H.;Wang, J. P.;Teng, C. M.;Kuo, S. C.
  11. Jpn. J. Pharmacol. v.76 no.2 Effect of PP1D-1, a synthetic antiplatelet compound, on rabbit platelets Liao, C. H.;Ko, F. N.;Kuo, S. C.;Teng, C. M.
  12. Biochem. Pharmacol. v.54 Thromboxane A₂synthase in-hibition and thromboxane A₂receptor blockade by 2-(4-cyanophenyl)amino-3-chloro-1,4-naphthalenedione(NQY-15) in rat platelets Chang, T. S.;Kim, H. M.;Lee, K. S.;Mar, W. C.;Ryu, C. K.;Moon, C. K.
  13. Arzneimittel-Forschung (Drug Res.) Studies on the antithrombotic and antiplatelet activities of NQ304, a newly synthesized naphthoquinone derivative Kang, W.S.;Joo, J. C.;Ryu, C. K.;Chung, K. H.;Ko, M. W.;Yuk, D. Y.;Yoo, H. S.;Yun, Y. P.
  14. J. Org. Chem. v.45 Reaction of 2.3-dichloro-1,4-naphthoquinone with arylamines in pyridine Argarwal, N. L.;Schaefer, W.
  15. J. Appl. Pharmacol. v.6 Effect of MCT(medium-chain triglyceride) and LCT(long-chain triglyceride) on myocardial ischemia/reperfusion injury and platelet aggregation in rat Lee, S. H.;Jung, Y. S.;Hong, J.;Kim, M. H.;Lee, H. J.;Baik, E. J.;Wang, H. J.;Kim, M. W.;Moon, C. H.
  16. J. Biol. Chem. v.269 Tight binding inhibitors of 85-Kda phospholipase A₂but not 14-KDa phospholipase A₂inhibit release of free arachidonate in thrombin-stimulated human platelets Bartoli, F.;Lin, H. K.;Ghomaschi, F.;Gelb, M. H.;Jain, M. K.;Apitz-Castro, R.
  17. Biochim. Biophys. Acta v.920 Evidence for the release of arachidonic acid through the selective action of phospholipase A₂in thrombin-stimulated human platelets Purdon, A. D.;Patelunas, D.;Smith, J. B.
  18. J. Clin. Invest. v.68 A role for prostaglandins and thromboxanes in the exposure of platelet fibrinogen receptors Bennett, J. S.;Vilaire, G.;Burch, J. W.
  19. Adv. Cyclic. Nucleotide Res. v.9 Reciprocal regulation of human platelet cAMP levels by thromboxane A₂and protacyclin Gorman, R. R.;Fitzpatrick, F. A.;Miller, O. V.
  20. Thromb. Res. v.40 Interaction of stable prostaglandin endoperoxide analogs U46619 and U44069 with human platelet membranes coupling of receptors with high-affinity GTPase and adenylate cyclase Avdonin, P. V.;Svitina-Ulltina, I. V.;Leytin, V. L.;Tkachuk, V. A.
  21. J. Biochem. v.103 Elevation of cytosolic free $Ca^{2+}$ is directly evoked by thromboxane A₂in human platelets during activation with collagen Moriyama, T.;Takamura, H.;Narita, H.;Tanaka, K.;Matsuura, T.;Kito, M.
  22. Biochem. J. v.219 Thromboxaneinduced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changed in cytosolic free calcium Pollock, W. K.;Armstrong, R. A.;Brydon, L. J.;Jones, R. L.Maclntyre, D. E.
  23. The platelets : physiology and pharmacology The lumiaggregometer as a research and tool Feinman, R. D.;Detwiler, T. C.;Ingerman-Wo-jeuski, C.;Longenecker, GL.(Ed.)